Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 128 The United Laboratories International Holdings Limited Annual Report 2025 32. SHARE-BASED PAYMENT TRANSACTIONS (Continued) Share award scheme (Continued) Weighted As at Granted Vested Lapsed Cancelled As at average fair 1 January during during during during 31 December value per Grantees Date of grant Vesting period 2024 the year the year the year the year 2024 award shares HK$ Directors Tsoi Hoi Shan 13 November 2023 13 November 2024 to 13 November 2026 575,100 – 191,700 – – 383,400 7.45 Leung Wing Hon 13 November 2023 13 November 2024 to 13 November 2026 401,100 – 133,700 – – 267,400 7.45 Choy Siu Chit 13 November 2023 13 November 2024 to 13 November 2026 268,800 – 89,600 – – 179,200 7.45 Fang Yu Ping 13 November 2023 13 November 2024 to 13 November 2026 186,900 – 62,300 – – 124,600 7.45 Zou Xian Hong 13 November 2023 13 November 2024 to 13 November 2026 186,900 – 62,300 – – 124,600 7.45 Zhu Su Yan 13 November 2023 13 November 2024 to 13 November 2026 186,900 – 62,300 – – 124,600 7.45 Employees 13 November 2023 13 November 2024 to 13 November 2026 10,291,200 – 3,004,280 426,120 – 6,860,800 7.45 Total 12,096,900 – 3,606,180 426,120 – 8,064,600 7.45 The fair value of award share is determined based on the closing price of the Group’s publicly traded ordinary shares on the date of grant. The Group has to estimate the expected yearly percentage of grantees that will stay within the Group at the end of the vesting periods of the award share (the “Expected Retention Rate”) in order to determine the amount of share-based compensation expenses charged to profit or loss. As at 31 December 2025, the Expected Retention Rate for the Group’s directors and employees was assessed to be 100%. The total expenses recognised in the consolidated statement of profit or loss and other comprehensive income for share-based awards granted to the Group’s directors and employees are RMB3,167,000 and RMB10,926,000 for the year ended 31 December 2025, respectively (2024: RMB7,069,000 and RMB40,295,000). As at 31 December 2025, 169,605,750 (2024: 169,605,750) award shares are available for future grant under the aforementioned scheme mandate limit.